Youngquist trust discloses 7.85M Coherus (CHRS) shares in 13G

Rhea-AI Filing Summary

Coherus Oncology, Inc. received a Schedule 13G reporting that the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 7,850,800 shares of its common stock. This represents 6.49% of the outstanding common shares, based on 120,871,013 shares outstanding as of October 31, 2025.

The trust has sole power to vote and dispose of these 7,850,800 shares. The position includes 560,000 shares underlying call options that are counted as beneficially owned because they are exercisable within 60 days. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Coherus Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

19249H103

(CUSIP Number)

02/05/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 19249H103

1

Names of Reporting Persons

Timothy G. Youngquist 2020 Irrevocable Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,290,800.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,290,800.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,850,800.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Trust

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coherus Oncology, Inc.
(b)	Address of issuer's principal executive offices: C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CALIFORNIA, 94065
Item 2.
(a)	Name of person filing: Timothy G. Youngquist 2020 Irrevocable Trust
(b)	Address or principal business office or, if none, residence: 15581 Pine Ridge Road Fort Myers, Fl 33908
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 19249H103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 7,850,800 shares of Common Stock
(b)	Percent of class: 6.49%.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 7,850,800
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 7,850,800
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Timothy G. Youngquist 2020 Irrevocable Trust
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. Trust
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Timothy G. Youngquist 2020 Irrevocable Trust

Signature:	Paul McCullers
Name/Title:	manager
Date:	02/05/2026

Comments accompanying signature: Outstanding shares. The percentage reported is based on 120,871,013 shares of the Issuer's common stock outstanding as of October 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025. Trust ownership. The shares reported herein are held by the Timothy G. Youngquist 2020 Irrevocable Trust, dated 2020, as amended and/or restated (the "Trust"), of which Trista Kragh is a trustee. Trista Kragh may be deemed to beneficially own such shares. Options included for beneficial ownership only. Includes 560,000 shares of common stock underlying call options that constitute a right to acquire shares within 60 days for purposes of Rule 13d-3. For purposes of calculating the Reporting Person's percentage of class, such underlying shares are deemed outstanding. The Reporting Person does not have voting or dispositive power over such underlying shares prior to exercise.

FAQ

What ownership stake in Coherus (CHRS) is reported by the Timothy G. Youngquist 2020 Irrevocable Trust?

The trust reports beneficial ownership of 7,850,800 Coherus shares, representing 6.49% of the common stock. This percentage is based on 120,871,013 shares outstanding as of October 31, 2025, as disclosed in Coherus’ Form 10-Q.

How was the 6.49% ownership percentage in Coherus (CHRS) calculated in this Schedule 13G?

The 6.49% ownership is calculated using 7,850,800 beneficially owned shares divided by 120,871,013 Coherus common shares outstanding as of October 31, 2025. That outstanding share figure comes from Coherus’ Form 10-Q filed November 6, 2025.

Who controls the Coherus (CHRS) shares held by the Timothy G. Youngquist 2020 Irrevocable Trust?

The filing states the shares are held by the Timothy G. Youngquist 2020 Irrevocable Trust, of which Trista Kragh is a trustee. The trust has sole voting and dispositive power over 7,850,800 Coherus common shares reported as beneficially owned.

Does the Coherus (CHRS) Schedule 13G include options in the reported ownership?

Yes. The reported 7,850,800 shares include 560,000 shares underlying call options. These options constitute a right to acquire Coherus common stock within 60 days, so they are counted as beneficially owned under Rule 13d-3 for percentage-of-class calculations.

Is the reported Coherus (CHRS) stake intended to influence control of the company?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Coherus, nor in connection with any transaction having that control-related purpose or effect.